product summary
Loading...
company name :
Bio X Cell
product type :
antibody
product name :
InVivoMab anti-human CD4
catalog :
BE0288-5MG
quantity :
5 mg
price :
350.00 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
RPA-T4
reactivity :
mouse
application :
immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - frozen section
more info or order :
citations: 6
Reference |
---|
Mack C, Tucker R, Sokol R, Karrer F, Kotzin B, Whitington P, et al. Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation. Pediatr Res. 2004;56:79-87 pubmed
|
Geijtenbeek T, Kwon D, Torensma R, van Vliet S, van Duijnhoven G, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587-97 pubmed
|
Moir S, Lapointe R, Malaspina A, Ostrowski M, Cole C, Chun T, et al. CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J Virol. 1999;73:7972-80 pubmed
|
product information
Catalog Number :
BE0288-5MG
Product Name :
InVivoMab anti-human CD4
Host Species :
mouse
Clonality :
Monoclonal
Conjugation :
No
Antigen Modification :
No
Product Type :
Antibody
Size :
5 mg
List Price :
$525.00
Acedemic Discount Price :
350.00 USD
list of Pubmed id :
27233453; 24055067; 21289125; 15128911; 10721995; 10482544;
Clone :
RPA-T4
Isotype :
IgG1, κ
Specificity :
human
Concentration :
Lot specific,typically between 2-10 mg/ml
Application Summary :
in vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry
Storage :
Undiluted at 4°C in the dark
more info or order :
company information

Bio X Cell
10 Technology Dr., Suite 2B
Lebanon, NH 03784-1671
Lebanon, NH 03784-1671
customerservice@bxcell.com
bxcell.com1-866-787-3444
headquarters: USA
related products
browse more products
questions and comments